Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

@article{Poordad2010VirologicRR,
  title={Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.},
  author={Fred F Poordad and Eric J. Lawitz and Mitchell L. Shiffman and Tarek I. Hassanein and Andrew J. Muir and Bruce R. Bacon and Jamie Heise and Deanine G. Halliman and Eric Chun and Janet M Hammond},
  journal={Hepatology},
  year={2010},
  volume={52 4},
  pages={1208-15}
}
UNLABELLED Ribavirin-induced hemolytic anemia can prompt dose reductions and lower sustained virologic response (SVR) rates in the treatment of patients with chronic hepatitis C. The study aimed to determine if weight-based dosing of taribavirin (TBV), an oral prodrug of ribavirin (RBV), demonstrated efficacy comparable to RBV while maintaining its previously demonstrated anemia advantage with fixed dose administration. A U.S. phase 2b randomized, open-label, active-controlled, parallel-group… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

HCV SPRINT - 1 final results : SVR 24 from a phase 2 study of boce - previr plus peginterferon - alpha 2 b / ribavirin in treatment - naı̈ve subjects with genotype 1 chronic hepatitis C

  • P Kwo, EJ Lawitz, J McCone, EG Schiff, J Vierling, D Pound
  • J Hepatol
  • 2009

HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus peginterferon-alpha2b/ribavirin in treatment-naı̈ve subjects with genotype 1 chronic hepatitis

  • P Kwo, EJ Lawitz, J McCone, EG Schiff, J Vierling, D Pound
  • C. J Hepatol 2009;50(Suppl 1):S4
  • 2009

Similar Papers

Loading similar papers…